Global Cancer Vaccine Market & Clinical Trial Insight 2025

Publish Date:- Sep-2018       No Of Pages (700)

Electronic Access - Single User License 3000 Buy Now
CD-ROM Mail Delivery 3800Buy Now
Hard Copy Mail Delivery 5100 Buy Now
Electronic Access - Multi-User License 5500 Buy Now


"Global Cancer Vaccine Market & Clinical Trial Insight 2025"  Report Highlight:

  • Global Cancer Vaccine market Opportunity: US$ 15 Billion opportunity
  • Personalized Cancer Vaccine: The Next growth Frontier
  • Global Cancer Vaccine Clinical insight by Indication & Phase of Development
  • Global Cancer Vaccine Pipeline: 369 Cancer Vaccines
  • Marketed Cancer Vaccines: 17 Cancer Vaccines
  • Maximum Vaccines in Pipeline for Brain & Breast Cancer:  43 Cancer Vaccines
  • Regulatory Landscape

 

Global cancer vaccine market opportunity is expected to surpass US$ 15 Billion by 2025 as per finding in new research report “Global Cancer Vaccine Market & Clinical Trial Insight 2025” published by PNS Pharma. In recent years, cancer vaccine segment as emerged as next growth frontier for the various stake holders involved in the research, development and commercialization of  cancer therapeutics. The market for cancer therapeutics is growing at significant rates and it has already occupied a major share in the overall pharmaceutical market.

Vaccines have had a good reputation when it comes to their safety and therapeutic outcome. The concept of vaccination has today paved a new path for treatment of complex disease like cancer, the cure for which is still highly limited to conventional therapeutics. However, with the emergence of immunotherapy, the cancer therapy segment has also advanced to a whole new level.

The application of the concept of vaccination to complex disease like cancer has grabbed immense attention in both academia and industries. Multiple clinical studies have shown that an ideal vaccine for cancer is in fact possible with the help of modern immunotherapy and advanced therapy. However, the study has further being extended with rigorous effort being put in the development of personalized cancer vaccine which are anticipated to have even better therapeutic outcome than cancer vaccines .

Owing to the advancement in science and technology along with the emergence of advanced computing, few cancer vaccines like cervarix for cervical cancer and provenge for prostate cancer have already entered the market. Both the vaccines are therapeutic vaccines which have shown excellent outcome in the clinical trials. The emergence of genome sequencing and ability to identify and target neo – antigens has led to the possibility of these vaccines being developed for many types of cancer in a more personalized form in the future. 

The cancer vaccine pipeline is expected to increase at tremendous rates in coming years. As large numbers of cancer vaccines are entering in various phases of clinical trials, due to which cancer market will soon observe a boost. However, the novelty of cancer vaccines makes it difficult for the standardization of clinical trials, because the criteria's required to quantify its effectiveness are not completely discovered, this cause loss of valuable time. Moreover, the present day methods are standardized for conventional cancer therapeutic methods like chemotherapy, radiotherapy and surgery, which are not applicable for cancer vaccines due to their different mode of actions. In near future, researchers will find the solution for this problem and it will decrease the winding time.

“Global Cancer Vaccine Market & Clinical Trial Insight 2025” report gives comprehensive insight on clinical and non-clinical parameters related to development and commercialization of cancer vaccines. As per report findings, there are 17 cancer vaccines commercially available in the market and more than 350 in the clinical pipeline. Most of the cancer vaccines in clinical pipeline are in Preclinical & Phase - II trials followed by Phase - I/II trials.  More than 5 new cancer vaccines are further expected to enter the market in next 10 years.


"Global Cancer Vaccine Market & Clinical Trial Insight 2025"  Report Highlight:

  • Global Cancer Vaccine market Opportunity: US$ 15 Billion opportunity
  • Personalized Cancer Vaccine: The Next growth Frontier
  • Global Cancer Vaccine Clinical insight by Indication & Phase of Development
  • Global Cancer Vaccine Pipeline: 369 Cancer Vaccines
  • Marketed Cancer Vaccines: 17 Cancer Vaccines
  • Maximum Vaccines in Pipeline for Brain & Breast Cancer:  43 Cancer Vaccines
  • Regulatory Landscape

 

Global cancer vaccine market opportunity is expected to surpass US$ 15 Billion by 2025 as per finding in new research report “Global Cancer Vaccine Market & Clinical Trial Insight 2025” published by PNS Pharma. In recent years, cancer vaccine segment as emerged as next growth frontier for the various stake holders involved in the research, development and commercialization of  cancer therapeutics. The market for cancer therapeutics is growing at significant rates and it has already occupied a major share in the overall pharmaceutical market.

Vaccines have had a good reputation when it comes to their safety and therapeutic outcome. The concept of vaccination has today paved a new path for treatment of complex disease like cancer, the cure for which is still highly limited to conventional therapeutics. However, with the emergence of immunotherapy, the cancer therapy segment has also advanced to a whole new level.

The application of the concept of vaccination to complex disease like cancer has grabbed immense attention in both academia and industries. Multiple clinical studies have shown that an ideal vaccine for cancer is in fact possible with the help of modern immunotherapy and advanced therapy. However, the study has further being extended with rigorous effort being put in the development of personalized cancer vaccine which are anticipated to have even better therapeutic outcome than cancer vaccines .

Owing to the advancement in science and technology along with the emergence of advanced computing, few cancer vaccines like cervarix for cervical cancer and provenge for prostate cancer have already entered the market. Both the vaccines are therapeutic vaccines which have shown excellent outcome in the clinical trials. The emergence of genome sequencing and ability to identify and target neo – antigens has led to the possibility of these vaccines being developed for many types of cancer in a more personalized form in the future. 

The cancer vaccine pipeline is expected to increase at tremendous rates in coming years. As large numbers of cancer vaccines are entering in various phases of clinical trials, due to which cancer market will soon observe a boost. However, the novelty of cancer vaccines makes it difficult for the standardization of clinical trials, because the criteria's required to quantify its effectiveness are not completely discovered, this cause loss of valuable time. Moreover, the present day methods are standardized for conventional cancer therapeutic methods like chemotherapy, radiotherapy and surgery, which are not applicable for cancer vaccines due to their different mode of actions. In near future, researchers will find the solution for this problem and it will decrease the winding time.

“Global Cancer Vaccine Market & Clinical Trial Insight 2025” report gives comprehensive insight on clinical and non-clinical parameters related to development and commercialization of cancer vaccines. As per report findings, there are 17 cancer vaccines commercially available in the market and more than 350 in the clinical pipeline. Most of the cancer vaccines in clinical pipeline are in Preclinical & Phase - II trials followed by Phase - I/II trials.  More than 5 new cancer vaccines are further expected to enter the market in next 10 years.

1. Introduction to Cancer Vaccines

 

2. Mechanism of Cancer Vaccines

  2.1 Idiotype Cancer Vaccine Mechanism

  2.2 Cellular Cancer Vaccines Mechanism

  2.3 Ganglioside Antigens based Cancer Vaccines Mechanism

  2.4 Peptide Cancer Vaccine Mechanism

  2.5 Tumor Host Interaction Cancer Vaccine Mechanism

 

3. Global Cancer Vaccines Market Overview

  3.1 Current Scenario

  3.2 Future Outlook

 

4. Personalized Cancer Vaccine: The Next growth Frontier

  4.1 The Possibility of a Personalized Cancer Vaccine

  4.2 An Insight into its Current Clinical Status

 

5. Personalized Cancer Vaccine: Current Market Scenario & Advancements

  5.1 Breakthrough in Research & Development

  5.2 Increasing Investments

  5.3 Integration of mRNA Technology

  5.4 Collaborations & Ventures

  5.5 Advancement in Technology

 

6. FDA Guideline for the Development & Marketing of Cancer Vaccines    

  6.1 Considerations for Both Early and Late Phase Clinical Trials

    6.1.1 Patient Population

    6.1.2 Monitoring The Immune Response

    6.1.3 Biomarkers As Evidence Of Efficacy

    6.1.4 Adjuvants Used To Stimulate Immune Response

    6.1.5 Multi-Antigen Vaccines

    6.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines

    6.1.7 Concomitant And Subsequent Therapies

  6.2 Considerations for Early Phase Clinical Trials

    6.2.1 Starting Dose And Dosing Schedule

    6.2.2 Booster And Maintenance Therapy

    6.2.3 Dose Escalation

    6.2.4 Single-Arm Versus Randomized Phase 2 Trials In Early Development

  6.3 Considerations For Late Phase Clinical Trials

    6.3.1 Safety Profile From Early Phase Clinical Trials

    6.3.2 Endpoints

    6.3.3 Statistical Issues

    6.3.4 Control Issues

    6.3.5 Delayed Vaccine Effect

    6.3.6 Autologous Vaccine Trials

    6.3.7 Accelerated Approval Regulations

 

7. Global Cancer Vaccines Clinical Pipeline Overview

  7.1 By Indication

  7.2 By  Mechanism of Action

  7.3 By  Drug Class

  7.4 By Patient Segment

  7.5 By Formulation

  7.6 By  Company

 

8. Global - Bladder Cancer Vaccine Clinical Pipeline by Phase & Company

  8.1 Phase-I/II

 

9. Marketed Bladder Cancer Vaccine Clinical Insight

  9.1 BCG Bladder Cancer Vaccine - sanofi pasteur

  9.2 Bladder Cancer Vaccine - Organon Teknika

  9.3 Bladder Cancer Vaccine - ID Biomedical

 

10. Global - Blood Cancer Vaccine Clinical Pipeline by Phase & Company

  10.1 Research

  10.2 Preclinical

  10.3 Phase-I

  10.4 Phase-I/II

  10.5 Phase-II

 

11. Global - Bone Cancer Vaccine Clinical Pipeline by Phase & Company

  11.1 Phase-II

  11.2 Phase-III

 

12. Global - Brain Cancer Vaccine Clinical Pipeline by Phase & Company

  12.1 Unknown

  12.2 Research

  12.3 Preclinical

  12.4 Phase-I

  12.5 Phase-I/II

  12.6 Phase-II

  12.7 Phase-III

 

13. Global - Breast Cancer Vaccine Clinical Pipeline by Phase & Company

  13.1 Research

  13.2 Preclinical

  13.3 Phase-I

  13.4 Phase-I/II

  13.5 Phase-II

  13.6 Phase-II/III

  13.7 Phase-III

 

14. Global - Cervical Cancer Vaccine Clinical Pipeline by Phase & Company

  14.1 Preclinical

  14.2 Clinical

  14.3 Phase-I

  14.4 Phase-II

  14.5 Phase-III

 

15. Marketed Cervical  Cancer Vaccine Clinical Insight

  15.1 Cervarix

 

16. Global - Colorectal Cancer Vaccine Clinical Pipeline by Phase & Company

  16.1 Research

  16.2 Preclinical

  16.3 Phase-I

  16.4 Phase-I/II

  16.5 Phase-II

  16.6 Phase-II/III

  16.7 Phase-III

 

17. Global - Kidney Cancer Vaccine Clinical Pipeline by Phase & Company

  17.1 Preclinical

  17.2 Phase-I

  17.3 Phase-II

  17.4 Phase-III

 

18. Marketed Kidney Cancer Vaccine Clinical Insight

  18.1 Vitespen (Oncophage)

  18.2 Dendritic Cell Vaccine (CreaVax-HCC, CreaVax-PC & CreaVax-RCC)

  18.3 Renal Cell Carcinoma Vaccine (Reniale)

 

19. Global - Liver Cancer Vaccine Clinical Pipeline by Phase & Company

  19.1 Phase-I/II

  19.2 Phase-II

  19.3 Phase-III

 

20. Global - Lung Cancer Vaccine Clinical Pipeline by Phase & Company

  20.1 Preclinical

 

21. Global - Mesothelioma Vaccine Clinical Pipeline by Phase & Company

  21.1 Phase-I

  21.2 Phase-II/III

 

22. Global - Head And Neck Cancer Vaccine Clinical Pipeline by Phase & Company

  22.1 Preclinical

  22.2 Phase-I

  22.3 Phase-I/II

  22.4 Phase-II

 

23. Global - Non Small Cell Lung Cancer Vaccine Clinical Pipeline by Phase & Company

  23.1 Research

  23.2 Clinical

  23.3 Phase-I

  23.4 Phase-I/II

  23.5 Phase-II

  23.6 Phase-II/III

  23.7 Phase-III

  23.8 Preregistration

 

24. Marketed Non Small Cell Lung Cancer Vaccine Clinical Insight

  24.1 Cadi 05 (Immuvac & Mycidac-C)

  24.2 Racotumomab (Vaxira)

  24.3 Epidermal Growth Factor Cancer Vaccine – Bioven

 

25. Global - Ovarian Cancer Vaccine Clinical Pipeline by Phase & Company

  25.1 Preclinical

  25.2 Phase-I

  25.3 Phase-I/II

  25.4 Phase-II

  25.5 Phase-III

 

26. Global - Prostate Cancer Vaccine Clinical Pipeline by Phase & Company

  26.1 Research

  26.2 Preclinical

  26.3 Phase-I

  26.4 Phase-I/II

  26.5 Phase-II

  26.6 Phase-III

 

27. Marketed Prostate Cancer Vaccine Clinical Insight

  27.1 Sipuleucel-T (Provenge)

 

28. Global - Pancreatic Cancer Vaccine Clinical Pipeline by Phase & Company

  28.1 Preclinical

  28.2 Phase-I

  28.3 Phase-I/II

  28.4 Phase-II

  28.5 Phase-III

 

29. Marketed Pancreatic Cancer Vaccine Clinical Insight

  29.1 Tertomotide (LucaVax)

 

30. Global - Skin Cancer Vaccine Clinical Pipeline by Phase & Company

  30.1 Preclinical

  30.2 Phase-I

  30.3 Phase-I/II

  30.4 Phase-II

  30.5 Phase-III

  30.6 Preregistration

 

31. Marketed Skin Cancer Vaccine Clinical Insight

  31.1 Melanoma Vaccine (MVax)

  31.2 Melanoma Vaccine (Melacine)

 

32. Global - Multiple Cancer Vaccine Clinical Pipeline by Phase & Company

  32.1 Research

  32.2 Preclinical

  32.3 Clinical

  32.4 Phase-I

  32.5 Phase-I/II

  32.6 Phase-II

  32.7 Phase-III

  32.8 Registered

 

33. Marketed Multiple Cancer Vaccine Clinical Insight

  33.1 Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9)

  33.2 Human Papillomavirus Vaccine Recombinant Quadrivalent (Gardasil & Silgard)

  33.3 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

 

34. Competitive Landscape

  34.1 Advaxis

  34.2 AVAX Technologies

  34.3 Dendreon Corporation

  34.4 Galena Biopharma

  34.5 GlaxoSmithKline

  34.6 ImmunoCellular Therapeutics

  34.7 ImmunoGen

  34.8 Inovio Pharmaceuticals

  34.9 KAEL-GemVax

  34.10 Liponova

  34.11 MedImmune

  34.12 Merck

  34.13 NeoStem Oncology

  34.14 NewLink Genetics

  34.15 Northwest Biotherapeutics

  34.16 Novartis

  34.17 Peregrine Pharmaceuticals

  34.18 Recombio

  34.19 Roche

  34.20 Sanofi

  34.21 Seattle Genetics

  34.22 Valeant Pharmaceuticals


Figure 1-1: Categorization & Function of Cancer Vaccines

Figure 2-1: Classification of Different Types of Cancer vaccines

Figure 3-1: Global - Cancer Vaccines Market Opportunity (US$ Billion), 2018-2025

Figure 3-2: Examples of Commercially Available Cancer Vaccines

Figure 4-1: Cancer Immunotherapeutics in the Development of Cancer Vaccine

Figure 4-2: Advantages of Targeting Neo – Antigens in Cancer Vaccine Production

Figure 5-1: Investments Generated by Key Market Players in the Personalized Cancer Segment (US$ Million), 2018

Figure 7-1: Global - Bladder Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-2: Global - Bladder Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-3: Global - Blood Cancer Vaccine Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-4: Global - Blood Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-5: Global - Bone Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7 6: Global - Bone Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-7: Global - Brain Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-8: Global - Brain Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-9: Global - Breast Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-10: Global - Breast Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-11: Global - Cervical Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-12: Global - Cervical Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-13: Global – Colorectal Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-14: Global – Colorectal Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-15: Global – Kidney Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-16: Global – Kidney Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-17: Global – Liver Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-18: Global – Liver Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-19: Global – Masothelioma Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-20: Global – Masothelioma Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-21: Global – Head and Neck Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-22 Global – Head and Neck Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-23: Global – Non Small Lung Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-24: Global – Non Small Lung Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-25: Global – Ovarian Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-26: Global – Ovarian Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-27: Global – Prostate Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-28: Global – Prostate Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-29: Global – Pancreatic Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-30: Global – Pancreatic Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-31: Global – Skin Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-32: Global – Skin Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-33: Global – Multiple Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-34: Global – Multiple Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-35: Total Global – Multiple Cancer Vaccines Clinical Pipeline by Phase (%), 2018 Till 2025

Figure 7-36: Total Global – Multiple Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 Till 2025

Figure 7-37: Global –Cancer Vaccines Clinical Pipeline by Mechanism of Action (%), 2018 Till 2025

Figure 7-38: Global –Cancer Vaccines Clinical Pipeline by Mechanism of Action (Number), 2018 Till 2025

Figure 7-39: Global – Cancer Vaccines Clinical Pipeline by Drug Class (%), 2018 Till 2025

Figure 7-40: Global – Cancer Vaccines Clinical Pipeline by Drug Class (Number), 2018 Till 2025

Figure 7-41: Global – Cancer Vaccines Clinical Pipeline by Patient Segment (%), 2018 Till 2025

Figure 7-42: Global – Cancer Vaccines Clinical Pipeline by Patient Segment (Number), 2018 Till 2025

Figure 7-43: Global – Cancer Vaccines Clinical Pipeline by Formulation (%), 2018 Till 2025

Figure 7-44: Global – Cancer Vaccines Clinical Pipeline by Formulation (Number), 2018 Till 2025

Figure 7-45: Global – Cancer Vaccines Clinical Pipeline by Company (%), 2018 Till 2025

Figure 7-46: Global – Cancer Vaccines Clinical Pipeline by Company (%), 2018 Till 2025